Last month, the Centers for Medicare & Medicaid Services began meeting with patients who use the 15 drugs it selected for the second round of Medicare price "negotiations" -- including ...

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...